DEINOVE is now ready to start Phase II clinical trial for its antibiotic compound DNV3837
Medpace Holdings, Inc. (MEDP)
Last medpace holdings, inc. earnings: 4/28 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.medpace.com
Company Research
Source: Business Wire
Having reached a sufficient number of clinical centers, Phase II clinical trial testing the antibiotic candidate DNV3837 in Clostridioides1 (Clostridium) difficile infections will start this summer in the United States and Germany This trial will be conducted as part of an active Investigational New Drug (IND) authorization and a recently updated version of the clinical protocol The production of the first commercial batch of DNV3837 has been successfully initiated MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: DEINOVE (Paris:ALDEI) (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics and nutrition, announced that all the conditions are in place for the upcoming start of the Phase II trial te
Show less
Read more
Impact Snapshot
Event Time:
MEDP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MEDP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MEDP alerts
High impacting Medpace Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
MEDP
News
- Medpace Holdings, Inc. (NASDAQ: MEDP) had its price target raised by analysts at Guggenheim from $453.00 to $464.00. They now have a "buy" rating on the stock.MarketBeat
- Medpace Holdings, Inc. (NASDAQ:MEDP) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Medpace Holdings, Inc. Just Beat EPS By 30%: Here's What Analysts Think Will Happen Next [Yahoo! Finance]Yahoo! Finance
- Medpace Holdings, Inc. (NASDAQ: MEDP) had its price target raised by analysts at Robert W. Baird from $446.00 to $454.00. They now have an "outperform" rating on the stock.MarketBeat
- Medpace Holdings, Inc. (NASDAQ: MEDP) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
MEDP
Earnings
- 4/22/24 - Beat
MEDP
Sec Filings
- 4/23/24 - Form 10-Q
- 4/22/24 - Form 8-K
- 4/3/24 - Form DEFA14A
- MEDP's page on the SEC website